A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S.